Orexo: Positive data from clinical phase I trial with OX640 - Redeye

Redeye is encouraged by the positive results from Orexo’s clinical phase I trial with the company’s nasal epinephrine (adrenaline), OX640, demonstrating proof-of-concept and bioavailability. We will return with a revised update on the case wherein we will review OX640 in more detail.

Länk till analysen i sin helhet: https://www.redeye.se/research/857698/orexo-positive-data-from-clinical-phase-i-trial-with-ox640?utm_source=finwire&utm_medium=RSS